Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL6584577

O=S(=O)(O)C(F)(F)F.Oc1cc(C(F)(F)F)ccc1Cl

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 2/20 0.44
TSHR P16473 2/20 0.44
ATM Q13315 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CHRNA7 P36544 1/20 0.43
MCL1 Q07820 5/20 0.43
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.41
MAPT P10636 2/20 0.40
KIF11 P52732 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
PDE2A O00408 1/20 0.40
KDM4E B2RXH2 1/20 0.40
CYP3A4 P08684 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL226137 0.87 ALDH1A1 (0.50) MEN1KMT2AALDH1A1TSHRATM
SCHEMBL29143042 0.85 ALDH1A1 (0.48) MEN1KMT2AALDH1A1TSHRATM
Ethylene Glycol SCHEMBL29238126 0.80 ALDH1A1 (0.43) MEN1KMT2AALDH1A1TSHRL3MBTL1
SCHEMBL27855804 0.75 ALDH1A1 (0.58) MEN1KMT2AALDH1A1TSHRATM
Trifluoromethanesulfonic Acid SCHEMBL28383106 0.74 KIF11 (0.61) KMT2ALMNAKIF11CA1CA2
SCHEMBL27855832 0.71 MRGPRX4 (0.47) MEN1KMT2AALDH1A1TSHRATM
SCHEMBL2725140 0.71 ALDH1A1 (0.58) MEN1KMT2AALDH1A1TSHRATM
SCHEMBL16555634 0.71 ALDH1A1 (0.58) MEN1KMT2AALDH1A1TSHRATM
SCHEMBL225921 0.71 PDE2A (0.53) MEN1KMT2AALDH1A1TSHRL3MBTL1
SCHEMBL29430111 0.71 PDE2A (0.53) MEN1KMT2AALDH1A1TSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1213025-C Thioamide derivatives HOFFMANN LA ROCHE (CH) 2005-08-03 CN disclosed
EP-1154993-B1 THIOAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2004-10-06 EP disclosed
US-6479666-B2 ANTIINFLAMMATORY AGENTS HOFFMAN-LA ROCHE INC. 2002-11-12 US disclosed
US-6458844-B2 ANTIINFLAMMATORY AGENTS HOFFMANN-LA ROCHE INC. 2002-10-01 US disclosed
US-6426348-B1 FOR THERAPY OF INFLAMMATION ASSOCIATED WITH CHRONIC INFLAMMATORY DISEASES SUCH AS RHEUMATOID ARTHRITIS (RA), MULTIPLE SCLEROSIS, (MS), ASTHMA, AND INFLAMMATORY BOWEL DISEASE (I BD) HOFFMANN-LA ROCHE INC. 2002-07-30 US disclosed
US-6423728-B1 INHIBIT BINDING OF VASCULAR CELL ADHESION MOLECULE-1 (VCAM-1) TO THE INTEGRIN VLA-4; USE AS ANTIINFLAMMATORY AGENTS AGAINST RHEMATOID ARTHRITIS, MULTIPLE SCLEROSIS, INFLAMMATORY BOWEL DISEASE AND ASTHMA HOFFMAN-LA ROCHE INC. 2002-07-23 US disclosed
US-20020052508-A1 Heterocyclic thioamide derivatives HULL KENNETH G (US) 2002-05-02 US disclosed
US-20020040148-A1 Diphenyl heterocyclic thioamide derivatives HULL KENNETH G (US) 2002-04-04 US disclosed
CN-1342140-A Thioamide derivatives HOFFMANN LA ROCHE (CH) 2002-03-27 CN disclosed
US-20020028933-A1 Thioamide derivatives HULL KENNETH GREGORY (US) 2002-03-07 US disclosed
US-20020010338-A1 PHENYL-KETO-IMIDAZOLIDINE THIOAMIDE DERIVATIVES HULL KENNETH G (US) 2002-01-24 US disclosed
EP-1154993-A1 THIOAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2001-11-21 EP disclosed
US-20010041799-A1 Diephenyl carbocyclic thioamide derivatives HULL KENNETH G (US) 2001-11-15 US disclosed
US-6288267-B1 AROMATIC CARBOXY THIOAMIDES WITH AMIDES AS DRUGS TO COUNTERACT INFLAMMATION HOFFMANN-LA ROCHE INC. 2001-09-11 US disclosed
WO-2000048994-A1 THIOAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2000-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028933-A1 Thioamide derivatives VCAM1, ICAM1, LTB4R MEN1 4163/4885KMT2A 1104/4885ALDH1A1 153/4885
US-20020010338-A1 PHENYL-KETO-IMIDAZOLIDINE THIOAMIDE DERIVATIVES VCAM1, ICAM1, KCNA4 MEN1 4461/4885KMT2A 275/4885ALDH1A1 243/4885
US-20020040148-A1 Diphenyl heterocyclic thioamide derivatives VCAM1, ICAM1, LTB4R MEN1 4244/4885KMT2A 1148/4885ALDH1A1 118/4885
US-20010041799-A1 Diephenyl carbocyclic thioamide derivatives VCAM1, ICAM1, LTB4R MEN1 4115/4885KMT2A 1171/4885ALDH1A1 232/4885
US-20020052508-A1 Heterocyclic thioamide derivatives VCAM1, ICAM1, LTB4R MEN1 3815/4885KMT2A 603/4885ALDH1A1 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.